What stage does NGN Capital invest at?

NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does NGN Capital focus on?

NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is NGN Capital located?

NGN Capital is headquartered in New York, US.

NGN Capital

Venture capital

New York · Series A–Late Stage · 5 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into NGN Capital

89 people in our graph share verified history with the NGN Capital team — schools, employers, funds. One of them is your warm intro.

Ben Caryunlockedknows Alexander Cuomo · together at Ithaca College

×9knows the team · via Pace University - Lubin School of Business

×2knows the team · via Ithaca College

✨ Fox Verdict

Investment thesis

NGN Capital is a venture capital firm dedicated to the healthcare sector, backing companies across biotech, pharmaceutical, and medical device fields. The team combines deep industry, clinical, and financial experience, drawing on backgrounds in pharmaceutical development, healthcare investment banking, corporate development, and drug and device approvals. Operating from New York and Heidelberg, Germany, the firm invests through U.S. and German funds totaling roughly $450 million.

Invests inBiotech Digital Health Healthtech Medical Devices Europe Germany Israel New York North America Stamford Switzerland United States

Source: firm website, verified Sep 15, 2026.

Stage

Series A–Late Stage

New York, Connecticut, US

Instruments

Equity

Founded

2004

AUM

$450M

VC funds

Tracked investments

Team · 5 people

from the firm's website & public directories

Ken Abramowitz· Co-Founder and Managing General Partner

Kenneth S. Abramowitz co-founded NGN Capital and serves as a Managing General Partner. He previously was a Managing Director and later Senior Advisor at The Carlyle Group in New York (2001-2003), where he focused on U.S. healthcare buyouts, and spent 23 years as an analyst at Sanford C. Bernstein & Co. covering the medical-supply, hospital-management, and HMO industries, followed by a role as a healthcare fund manager at EGS Securities. He holds a B.A. from Columbia University and an M.B.A. from Harvard Business School.

k•••@ngncapital.comreveal

Kenneth J. Gorelick· Venture Partner

A physician with three decades of experience developing drugs, biologics, and medical devices. He has held senior clinical development roles at Dupont Merck and Genelabs and serves as a consultant to the biopharmaceutical industry.

William J. Gedale· Senior Advisor

Senior Advisor and co-founder of NGN Capital with an investment career dating to 1965. He founded Mount Everest Advisors, consulted for Warburg-Pincus, and led General American Investors as President and CEO.

Alexander Cuomo· Chief Financial Officer· Stamford, Connecticut, United Statesin

CFO of NGN Capital since 2008, responsible for financial reporting, tax and audit compliance, portfolio valuation, budgeting, and investor relations across the U.S. and German funds. He holds a master's in finance from Pace University.

a•••@ngncapital.comreveal

Peter Johann· Managing General Partner

Managing General Partner at NGN Capital with a background in biotech and pharmaceutical business development, having previously held senior corporate development, licensing, and marketing roles at Boehringer Ingelheim, F. Hoffmann-La Roche, and Boehringer Mannheim. He holds a Ph.D. from the Technical University Munich and serves on several life sciences company boards including Exosome Diagnostics and Vivaldi Biosciences.

p•••@ngncapital.comreveal

What they invest in

from 3 of 3 portfolio companies

Biotech ×3Healthtech ×2Medical Devices ×1

HQs:United States×3

Investments · 3 tracked

founders shown can be your intro path

Vivaldi Biosciencesvivaldibiosciences.com✓ verified

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.

BiotechHealthtechMedical DevicesFort Collins, US

Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)

Co-investorsBay City Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Neurotrope Exosome Diagnostics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Portfolio news

latest coverage across their companies

Exosome Diagnostics Market - Strategic Insights and Forecasts (2026-2031)

Exosome Diagnostics · globenewswire.com · Jul 7, 2026

Fund performance · per public LP disclosures · 2

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
NGN BioMed Opportunity IILPs: New York City Police Pension Fund	2008	—	0.6%	1.05x	1.05x
NGN BioMed Opportunity II, L.P.LPs: New York City Employees' Retirement System, Teachers' Retirement System of the City of New York, New York City Police Pension Fund +1 more	2008	—	0.6%	1.05x	1.05x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does NGN Capital invest at?: NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does NGN Capital focus on?: NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is NGN Capital located?: NGN Capital is headquartered in New York, US.

Similar investors

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

$500K – $10M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

$100K – $15M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

$1M – $75M